Cara Therapeutics Inc (CARA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruritus. Its lead product candidate includes KORSUVA injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, and dialysis of patients suffering from uremic pruritus. Cara Therapeutics develops molecules at novel analgesic and anti-inflammatory targets using proprietary drug screening technology. The company serves pharmaceutical and healthcare sectors. Cara Therapeutics is headquartered in Stamford, Connecticut, the US.

Cara Therapeutics Inc (CARA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 12
Cara Therapeutics Enters Into Licensing Agreement With Maruishi Pharma For CR845 14
Cara Therapeutics Enters Into Licensing Agreement With Chong Kun Dang Pharma For CR845 16
Chong Kun Dang Pharmaceutical Corp (CKD Pharma) manufactures, distributes, imports and exports prescription drugs, active pharmaceutical ingredients (APIs), over-the-counter (OTC) drugs, health supplements and consumer health products. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colors; aerosols; mat vaporizers and mosquito coils; and others. The companys Chong Kun Dang Research Institute is characterized by three independent laboratories, namely, The New Drug Discovery Labs; The Technology Development Labs; and the Bio Research Labs. The company has presence in Korea, Japan, Vietnam and China. CKD Pharma is headquartered in Seoul, South Korea. 17
Cara Therapeutics Inc - Key Competitors 18
Cara Therapeutics Inc - Key Employees 19
Cara Therapeutics Inc - Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Aug 07, 2018: Cara Therapeutics Reports Second Quarter 2018 Financial Results 21
May 09, 2018: Cara Therapeutics Reports First Quarter 2018 Financial Results 23
Mar 15, 2018: Cara Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 25
Nov 02, 2017: Cara Therapeutics Reports Third Quarter 2017 Financial Results 28
Aug 03, 2017: Cara Therapeutics Reports Second Quarter 2017 Financial Results 30
May 04, 2017: Cara Therapeutics Reports First Quarter 2017 Financial Results 32
Mar 09, 2017: Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 34
Product News 36
10/17/2017: Cara Therapeutics Announces Participation in ANESTHESIOLOGY 2017 36
08/01/2017: Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer 37
06/27/2018: Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery 38
06/23/2017: Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients 39
05/17/2017: Cara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics 40
05/14/2018: Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting 41
05/12/2017: Cara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus 42
04/10/2018: Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation 43
03/28/2017: Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus 44
Clinical Trials 46
Jul 19, 2018: Enteris BioPharmas Feasibility-to-Licensing Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA 46
Jul 11, 2018: Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients 47
Feb 28, 2018: Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA (CR845/difelikefalin) in Chronic Liver Disease Patients 48
Jan 31, 2018: Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus 49
Oct 31, 2017: Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting 50
Oct 31, 2017: Enteris BioPharmas "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients 51
Oct 25, 2017: Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients 52
Oct 16, 2017: Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus 53
Oct 16, 2017: Cara Therapeutics to Present Data at Kidney Week 2017 54
Oct 04, 2017: Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference 55
Aug 31, 2017: Cara Therapeutics to Participate in September Medical Meetings 56
Jul 12, 2017: Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease 57
Jun 29, 2017: Cara Therapeutics Announces Top-line Results From Phase 2b Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Hip or Knee 58
Jun 21, 2017: Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment 59
Apr 24, 2017: Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List Of Tables


Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 12
Cara Therapeutics Enters Into Licensing Agreement With Maruishi Pharma For CR845 14
Cara Therapeutics Enters Into Licensing Agreement With Chong Kun Dang Pharma For CR845 16
Cara Therapeutics Inc, Key Competitors 18
Cara Therapeutics Inc, Key Employees 19

List Of Figures


Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Zucara Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Zucara Therapeutics Inc (Zucara Therapeutics) is a pharmaceutical company that develops novel drug therapies to prevent hypoglycemia in people with diabetes. The companys technology is used to prevent the dangerous

USD 250 View Report

Cara Therapeutics Inc (CARA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the

USD 250 View Report

Assertio Therapeutics Inc - Strategy, SWOT and Corporate Finance Report

Assertio Therapeutics Inc - Strategy, SWOT and Corporate Finance ReportAssertio Therapeutics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Yumanity Therapeutics Inc (YMTX) - Financial and Strategic SWOT Analysis Review

Yumanity Therapeutics Inc (YMTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available